Epigenetic modulation has been important in the development of oncology therapies, but its use in cardiovascular diseases is just beginning. In this pre-BIO interview, Sten Sörensen from Cereno Scientific provides some insights into developments in this field.

Prior to BIO 2025, Russell Miller from Enzene Biosciences highlights how a fully connected continuous manufacturing platform is enhancing biologics production and, hence, improving patient access.

Solid tumors are difficult to treat as a result of numerous factors, in this interview, Oury Chetboun from Seekyo Therapeutics, details how targeting functional proteins in the tumor microenvironment can help.

Treating metastases with an external laser beam can prove challenging; however, radiotherapeutics are providing more targeted treatment options, radiating the tumor cells from within, specifies David Bejker from Affibody.

Elin Trampe from Dicot Pharma emphasizes the need for innovation in the field of potency drugs, which has been dominated by PDE5 inhibitors, and provides details of an approach that is offering new potential.

The development and manufacture of personalized therapies are challenging for a variety of reasons; however, novel tools that are fit-for-purpose are becoming available, notes Luc Henry from Limula.

For David Westberg from Nanexa, long-acting injectables will continue to see growth in the field of mental health conditions and will also experience dramatic growth in other indication areas, such as Type 2 diabetes and obesity.

Multi-omics is allowing oversight into the relationships between the different layers of cells, allowing for the creation of new types of drugs and treatment strategies, explains Juozas Gordevičius from VUGENE.

Ahead of BIO 2025, Monika Paulė from Caszyme reveals details about a new CRISPR family, Cas12l, which is smaller than Cas9, meaning it could be a good alternative option for companies with certain limitations.

The complexities of next-generation therapies are pushing the boundaries of development and manufacture, leading to an increased need for advanced technologies and novel approaches to processes.

During Pharmatag 2025, Syntegon presented its new SynTiso aseptic filling line at Pharmatag 2025, which has been developed in collaboration with partners from the pharmaceutical industry to meet the increasing need for flexibility, contamination control, and Annex 1 compliance.

The new DPI filling technology is an enhanced equivalent to the original filling system for the GSK Diskus DPI and will be available to manufacturers looking to produce generic products from the original Diskus and Ellipta products.

The company’s MLD Advanced uses a combination of proven technologies to enable manufacturers to quickly and efficiently meet the requirements of high outputs.

India’s pharmaceutical industry has long been synonymous with cost-effective pharmaceutical manufacturing - particularly when it comes to generic drugs. In recent years, India has been making a significant shift from low-cost generic drug production into CDMO services.

The global biologics market is expected to reach USD 720 bn by 2030 - fueled by the increasing demand for biologics, biosimilars, and advanced therapies - and is undoubtedly an area of keen interest for CDMOs specializing in biologics.

The CDMO industry saw significant growth in 2024, as biotech and pharmaceutical companies continued the trend toward outsourcing R&D activities. This surge was evident in the global CDMO market value, which ended the year with a valuation of USD 185 billion.

Pharmaceutical industry deals have hit a decade-low in 2024, with only 558 deals totalling USD 67.2 bn by late November - the lowest since 2016. The largest biotech purchase of 2024, Vertex's USD 4.9 bn acquisition of Alpine Immune Sciences, is dwarfed by Pfizer's USD 43 bn Seagen takeover in 2023.

The decline in major acquisitions can be attributed to several factors: pharma companies digesting previous large deals, high valuations of listed biotech's deterring potential buyers, a focus on smaller, "bolt-on" deals under USD 5 bn, and antitrust concerns and political uncertainty in an election year.

Aizon has raised $20 million in Series C financing, with NewVale Capital leading the round with support from current backers. This funding boost is set to advance their AI-based platform for pharmaceutical manufacturing and aid in deploying their latest electronic batch record (eBR) system.

Sponsored by Expert Insights and Orientation Marketing, a panel of senior executives from the development and manufacturing partners charged with scaling and supplying medicines to patients were optimistic about 2024, but reflected on some of the challenges the industry will face too.

Brought to you by Orientation Marketing, hear thought-provoking views from five experienced c-level executives from leading development, technology, manufacturing, and bioprocessing partners.